BioSpace News Archive

Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases,

Allonnia LLC, a bioremediation company, launched today with $40 million in Series A funding to find new answers to the growing challenge of waste management.

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two investor conferences in November.

Lexogen, a transcriptomics and Next-Generation Sequencing company today announced the introduction of the LUTHOR 3' mRNA-Seq Library Prep Kit

By uniting with The Network, Alliance Cancer Specialists and Northwest Oncology strengthen their ability to deliver advanced cancer care in local communities

AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the second annual Cancer Community (C2) Awards. A part of the YOUR Cancer program, the C2 Awards celebrate grassroots organizations and individuals making impactful change in the cancer community.

Vidence, an oncology informatics company, and NTT DATA Services, a global digital business and IT services leader, today announced a relationship to build advanced artificial intelligence (AI) and machine learning (ML) algorithms to predict patient outcomes, enhance decision-making, and drive clinical trials to advance cancer research and treatment

Noveome Biotherapeutics, Inc ., a clinical stage biopharmaceutical company focused on developing next-generation biologics for the restoration of cellular integrity of damaged tissues, has appointed M. Michelle Berrey, M.D., M.P.H. and Annamaria T. Kausz, M.D., M.S. as members of the company’s Board of Directors. “We are delighted to welcome Drs. Berrey and Kausz to our Board of Directors. Each brings a wealth of e

InVivo Therapeutics Holdings Corp. (NVIV) today announced the pricing of a public offering of 18,750,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), together with warrants to purchase up to 18,750,000 shares of common stock at a combined effective price to the public of $ 0.80 per share (or pre-funded warrant) and associated warrant. The gross proceeds from this offering

Todos Medical (OTCQB:TOMDF) (“Todos”) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, along with Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) , a clinical-stage biopharmaceutical company focused on the developmen